durvalumab,tremelimumab
astrazeneca
[]
first rectal, now gastric/gej! thanks to for sharing results from the infinity trial of neoadjuvant durva/treme. excited to see this approach explored in more gi cancer types. #gi23 
MD/PhD Heme/Onc fellow @WUSTL || GI cancers, single-cell genomics || https://t.co/m7AbNIgoLw || @MichaelIglesia@med-mastodon.com || Views are my own.